Loading...
•
Mar 31, 2024
Mimedx Q1 2024 Earnings Report
Mimedx reported a stellar first quarter with robust net sales growth and disciplined expense management.
Key Takeaways
MiMedx Group, Inc. announced strong first quarter 2024 results, with net sales of $85 million, representing an 18% increase year-over-year. The company reported GAAP net income of $9 million and an Adjusted EBITDA of $19 million, or 22% of net sales. They also expanded their portfolio with a distribution agreement for a new xenograft product.
Net sales for Q1 2024 reached $85 million, an 18% increase year-over-year.
GAAP net income for Q1 2024 was $9 million, resulting in a net margin of 11%.
Adjusted EBITDA for Q1 2024 was $19 million, representing 22% of net sales.
The company expanded its portfolio through a distribution agreement with Regenity Biosciences for a collagen particulate xenograft product.
Revenue by Segment
Forward Guidance
MIMEDX is positioned well for another successful year and long-term growth due to the clinical strength of its product portfolio, the effectiveness of its commercial organization, a solid financial foundation, and the pending launch of its xenograft product into the Surgical market.
Positive Outlook
- Clinical strength of product portfolio
- Effectiveness of commercial organization
- Solid financial foundation
- Pending launch of xenograft product into the Surgical market
- Disciplined expense management
Challenges Ahead
- Future sales are uncertain and affected by competition
- Access to customers and healthcare providers can vary
- Reimbursement environment fluctuations
- Scientific research results are uncertain and may have little or no value
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...